CellCarta To Include Tempus In CDx Commercialization Lab Network As Network's Second Commercial Laboratory Partner, Enhancing Oncology Companion Diagnostics For Biopharma
Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model.MONTREAL, Aug. 6, 2026 /PRNewswire/ -- CellCarta, a global CRO laboratory
Tempus joined CellCarta's network to help test cancer medicines faster and better. When companies partner like this, it shows they're building something bigger together—watch if more partners join, which hints the idea is working.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.